298 related articles for article (PubMed ID: 33182025)
1. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
Li M; Zeng C; Yao J; Ge Y; An G
Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
[TBL] [Abstract][Full Text] [Related]
2. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
3. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
4. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
[TBL] [Abstract][Full Text] [Related]
6. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
[TBL] [Abstract][Full Text] [Related]
7. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
[TBL] [Abstract][Full Text] [Related]
10. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Qin BD; Jiao XD; Zhou XC; Shi B; Wang J; Liu K; Wu Y; Ling Y; Zang YS
Oncoimmunology; 2021; 10(1):1929727. PubMed ID: 34350061
[TBL] [Abstract][Full Text] [Related]
11. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
[TBL] [Abstract][Full Text] [Related]
12. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
Deng R; Zhang H; Li Y; Shi Y
J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
[TBL] [Abstract][Full Text] [Related]
13. Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients.
Wu B; Sun C; Sun X; Li X
Medicine (Baltimore); 2022 Sep; 101(36):e30532. PubMed ID: 36086697
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
[TBL] [Abstract][Full Text] [Related]
15. Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Dar S; Merza N; Qatani A; Rahim M; Varughese T; Mohammad A; Masood F; Reza FZ; Wan S; Almas T
Ann Med Surg (Lond); 2022 Jun; 78():103752. PubMed ID: 35600176
[TBL] [Abstract][Full Text] [Related]
16. The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis.
Wei N; Zheng B; Que W; Zhang J; Liu M
Br J Clin Pharmacol; 2022 Jul; 88(7):3052-3063. PubMed ID: 35165922
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
18. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Li C; Xia Z; Li A; Meng J
Ann Transl Med; 2020 Dec; 8(24):1655. PubMed ID: 33490167
[TBL] [Abstract][Full Text] [Related]
19. The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Hu DH; Wong WC; Zhou JX; Luo J; Cai SW; Zhou H; Tang H
J Oncol; 2022; 2022():1001796. PubMed ID: 35855807
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
